Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD)

Subjects

Abstract

Infantile myopathies with diaphragmatic paralysis are genetically heterogeneous, and clinical symptoms do not assist in differentiating between them. We used phased haplotype analysis with subsequent targeted exome sequencing to identify MEGF10 mutations in a previously unidentified type of infantile myopathy with diaphragmatic weakness, areflexia, respiratory distress and dysphagia. MEGF10 is highly expressed in activated satellite cells and regulates their proliferation as well as their differentiation and fusion into multinucleated myofibers, which are greatly reduced in muscle from individuals with early onset myopathy, areflexia, respiratory distress and dysphagia.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Mutations in MEGF10 cause EMARDD, a recessive congenital myopathy.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Grohmann, K. et al. Nat. Genet. 29, 75–77 (2001).

    Article  CAS  Google Scholar 

  2. Guenther, U.P. et al. J. Mol. Med. 87, 31–41 (2009).

    Article  CAS  Google Scholar 

  3. Guenther, U.P. et al. Hum. Mutat. 28, 808–815 (2007).

    Article  CAS  Google Scholar 

  4. Grohmann, K. et al. Hum. Mol. Genet. 13, 2031–2042 (2004).

    Article  CAS  Google Scholar 

  5. Maddatu, T.P. et al. Hum. Mol. Genet. 13, 1105–1115 (2004).

    Article  CAS  Google Scholar 

  6. Pitt, M. et al. Brain 126, 2682–2692 (2003).

    Article  Google Scholar 

  7. Hartley, L. et al. Neuromuscul. Disord. 17, 174–179 (2007).

    Article  CAS  Google Scholar 

  8. Carr, I.M. et al. Hum. Mutat. 30, 960–967 (2009).

    Article  CAS  Google Scholar 

  9. Seelow, D. et al. Nucleic Acids Res. 37, W593–W599 (2009).

    Article  CAS  Google Scholar 

  10. Suzuki, E. et al. Exp. Cell Res. 313, 3729–3742 (2007).

    Article  CAS  Google Scholar 

  11. Suzuki, E. et al. Exp. Cell Res. 313, 2451–2464 (2007).

    Article  CAS  Google Scholar 

  12. Hamon, Y. et al. PLoS ONE 1, e120 (2006).

    Article  Google Scholar 

  13. Wu, H.H. et al. Nat. Neurosci. 12, 1534–1541 (2009).

    Article  CAS  Google Scholar 

  14. Nagase, T. et al. DNA Res. 8, 85–95 (2001).

    Article  CAS  Google Scholar 

  15. Holterman, C.E. et al. J. Cell Biol. 179, 911–922 (2007).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the families who participated in this study. F.M. is supported by the Great Ormond Street Hospital Children's Charity. Z.A.A. receives an Egyptian Government Scholarship. This work was supported by grants from Newlife Foundation for Disabled Children (to I.M.C. and C.A.J.) and the Sir Jules Thorn Award for Biomedical Research (to C.A.J., E.S., G.R.T. and D.T.B.), the Deutsche Forschungsgemeinschaft (SFB 665 TP C4 and KFO 192) and the NeuroCure Cluster of Excellence, Exc 257 (to M. Schuelke) and the parents' support group 'Helft dem muskelkranken Kind' Hamburg, Germany (to C.H.). We acknowledge the contribution of clinical data by U. Schara and T. Polster.

Author information

Authors and Affiliations

Authors

Contributions

K.S., M. Schuelke and I.M.C. performed genetic mapping. C.V.L., B.L., D.A.P., C.P.D., G.M., M. Schuelke and C.A.J. performed mutation analyses in the cohorts of affected individuals. C.V.L., J.E.M., D.A.P. and G.R.T. generated the next-generation sequencing data. C.V.L. and D.A.P. performed the control genotyping. D.A.P., I.M.C., M. Schuelke and G.R.T. analyzed the SNP genotyping and next-generation sequencing data. C.V.L. examined the complementary DNA and protein expression in cell lines from affected individuals. Z.A.A. and M. Shires performed the immunohistochemistry staining experiments. C.P., A.v.R., I.E., A.F.M., T.H., E.S., C.H., F.M., A.Y.M., M. Scoto and M. Schuelke recruited subjects, gathered clinical information and contributed clinical samples. A.F.M., D.T.B., E.S., F.M., I.M.C., C.H., M. Schuelke and C.A.J. wrote the manuscript.

Corresponding authors

Correspondence to Markus Schuelke or Colin A Johnson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–5, Supplementary Tables 1 and 2, Supplementary Methods and Supplementary Note. (PDF 2074 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Logan, C., Lucke, B., Pottinger, C. et al. Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD). Nat Genet 43, 1189–1192 (2011). https://doi.org/10.1038/ng.995

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.995

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing